Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMIZE: Antibiotics + Enzalutamide in mCRPC
NCT06126731Phase 2Recruiting
- Sponsor
- The Institute of Cancer Research
- Start
- Nov 2023
- Primary completion
- Jun 2026
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of amoxicillin, metronidazole, vancomycin, ciprofloxacin in metastatic castration-resistant prostate cancer (mCRPC), sponsored by The Institute of Cancer Research. Started Nov 2023; status: recruiting.
02
Drugs
amoxicillinmetronidazolevancomycinciprofloxacin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06126731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126731.